Dmitri Grebennik

557 total citations
10 papers, 233 citations indexed

About

Dmitri Grebennik is a scholar working on Oncology, Molecular Biology and Economics and Econometrics. According to data from OpenAlex, Dmitri Grebennik has authored 10 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Economics and Econometrics. Recurrent topics in Dmitri Grebennik's work include CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cutaneous Melanoma Detection and Management (2 papers). Dmitri Grebennik is often cited by papers focused on CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cutaneous Melanoma Detection and Management (2 papers). Dmitri Grebennik collaborates with scholars based in United States, France and Spain. Dmitri Grebennik's co-authors include Hagop Youssoufian, Patrick Schöffski, Alby Elias, Piotr Rutkowski, Jean‐Yves Blay, Gregory Pennock, Thierry Gil, Hans Gelderblom, Shande Tang and Jan Cosaert and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Dmitri Grebennik

9 papers receiving 227 citations

Peers

Dmitri Grebennik

ONCOL

PRM

EDM

IMMUN

Jennifer Kherani United States

Karim Boudadi United States

Beili Gao China

Sierra Min Li United States

David T. Hoang United States

Jingyu Ma China

Yasuyuki Kanke Japan

Kiyoyuki Kobayashi Japan

Qinghai Ji China

Augusto Bleve Italy

Jennifer Kherani United States

Dmitri Grebennik

113 ×0.8

ONCOL

65 ×0.6

104 ×1.5

PRM

54 ×1.2

EDM

16 ×0.4

IMMUN

Citations per year, relative to Dmitri Grebennik Dmitri Grebennik (= 1×) peers Jennifer Kherani

Countries citing papers authored by Dmitri Grebennik

Since Specialization

Citations

This map shows the geographic impact of Dmitri Grebennik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitri Grebennik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitri Grebennik more than expected).

Fields of papers citing papers by Dmitri Grebennik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitri Grebennik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitri Grebennik. The network helps show where Dmitri Grebennik may publish in the future.

Co-authorship network of co-authors of Dmitri Grebennik

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitri Grebennik. A scholar is included among the top collaborators of Dmitri Grebennik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitri Grebennik. Dmitri Grebennik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Whitman, Eric D., et al.. (2024). Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US. BMC Cancer. 24(1). 389–389.

Mortier, Laurent, Lisa Villabona, Ben Lawrence, et al.. (2024). Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. American Journal of Clinical Dermatology. 25(6). 987–996. 3 indexed citations

Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations

Aguiar‐Ibáñez, Raquel, et al.. (2023). Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients. BMC Health Services Research. 23(1). 136–136. 3 indexed citations

Eggermont, Alexander M.M., Michal Kiciński, Mario Mandalà, et al.. (2022). 804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology. 33. S912–S913. 1 indexed citations

Aguiar‐Ibáñez, Raquel, et al.. (2021). 897 Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US). Regular and Young Investigator Award Abstracts. A941–A941. 1 indexed citations

Khalil, Danny N., Michael A. Postow, Nageatte Ibrahim, et al.. (2016). An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research. 22(21). 5204–5210. 19 indexed citations

Gradishar, William J., Denise A. Yardley, Rachel M. Layman, et al.. (2015). Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clinical Cancer Research. 22(2). 301–309. 54 indexed citations

Schöffski, Patrick, Jean‐Yves Blay, Thierry Gil, et al.. (2013). An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. European Journal of Cancer. 49(15). 3219–3228. 72 indexed citations

10.

LoRusso, Patricia, Smitha Krishnamurthi, Hagop Youssoufian, et al.. (2013). Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Investigational New Drugs. 32(2). 303–311. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact